-
JBCRG-01
Study of cyclophosphamide, epirubicin and fluoraouracil followed by docetaxel (CEF-DOC) as preoperative chemotherapy in primary operable breast cancer
- Status
-
Study Closed
- Objectives
-
The purpose of this study is to evaluate the feasibility and safety as well as clinical and pathological response of cyclophosphamide, epirubicin and fluorouracil (CEF) followed by docetaxel (DOC) as primary systemic chemotherapy in patients with operable breast cancer.
- Subjects
-
- Endpoints
-
Primary endpoint: Clinicl response, pathologic response, safety, Secondary endpoints: Breast-conserving rate, overall survival, disease free survival
- Trial Period
-
June 2002 - May 2009 (Registration: 2 years, follow-up study: 5 years)
- Lead Principal Investigator
-
Yuichi Takatsuka (Department of Breast Surgery, Kansai Rosai Hospital), Masakazu Toi (Department of Surgery, Breast Surgery, Graduate School of Kyoto University)
- Target Sample Size
-
202
- Regimen
-
FEC100 q3w x4->Doc75 q3wx4
- Source of Funding
-
ACRO: Advanced Clinical Research Organization
- Conference Presentation
-
The effect of pathological response of multicenter phase II trial of fluorouracil, epirubicin, cyclophosphamide (FEC 100) followed by docetaxel (DOC 75) in primary operable breast cancer.
- Articles and Publications
-
Comparison of different definitions of pathologic complete response in operable breast cancer; a pooled analysis of three prospective neoadjuvant studies of JBCRG
Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer.
Docetaxel Followed by Fluorouracil/Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy for Patients With Primary Breast Cancer
PhaseII study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival
Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer.
Update results of FEC followed by docetaxel neoadjuvant trials for primary breast cancer
Interim analysis of a phaseII trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breastcarcinoma
- UMIN-ID
-
C000000011
- jRCT
-
- Memo
-
- COI Disclosure
-
